From JPMA Toward the Creation of a Healthcare Ecosystem that Generates Continuous Innovation
During the COVID-19 pandemic, we, the JPMA and its member companies, were reminded once again of the mission of pharmaceutical companies, which is the early creation of treatments and vaccines and the stable supply of medicines. In June 2020, JPMA released its proposal on countermeasures against infectious diseases and has been in dialogue with the government to accelerate the development of domestically produced vaccines. In preparation for a possible future pandemic, we will collaborate with the government on preparations from normal times to develop an immediate response system in case of an emergency under the government's "Strategy for Strengthening Vaccine Development and Production Systems".
In order to meet the unmet medical needs that still exist in Japan's super-aging society through the creation of innovative new drugs and protect the lives and health of the Japanese people, it is essential to strengthen Japan's drug discovery capabilities. This will require the formation of life science clusters that organically link human resources with a strong entrepreneurial spirit, venture companies conducting cutting-edge research, and various research institutions; the development of a big data infrastructure that combines cutting-edge digital technologies to create innovative solutions; and the establishment of a drug pricing system that appropriately evaluates the innovations that are created. The NHI drug price system must be established to appropriately evaluate the innovations created. It is important to build a pharmaceutical industry infrastructure, or healthcare ecosystem, in Japan with these core components. The pharmaceutical companies that form the core of this ecosystem will do their utmost to contribute to the extension of healthy life expectancy of the Japanese people and to Japan's economic growth through a barrage of innovations.
Japan Pharmaceutical Manufacturers Association
Yasushi Okada, Chairman
We will also contribute to global health by promoting international expansion and international cooperation through partnerships with overseas industry associations and dialogues with foreign governments, and by delivering innovative new medicines to patients around the world.
The JPMA is currently undergoing various changes in the environment surrounding the pharmaceutical industry, and in the midst of accelerating digital transformation (DX) under the COVID-19 pandemic, the JPMA will release an addendum to the "JPMA Industry Vision 2025" in May 2021 to promote efficiency in drug discovery research, clinical development, and information provision by utilizing digital technology. In May 2021, the Pharmaceutical Manufacturers Association of Japan (PMAJ) released a supplemental version of the "PMAJ Industry Vision 2025" to promote efficiency in drug discovery research, clinical development, and information provision by utilizing digital technology. We are also working on environmental issues to realize carbon neutrality, including participation in the "Voluntary Action Plan for Establishing a Recycling-Oriented Society" of the Japan Federation of Pharmaceutical Manufacturers' Associations (JFPMA). In order to fulfill its mission in the ever-changing social climate, the pharmaceutical industry will continue to make changes in order to gain the strong trust and understanding of the public.
(From a contribution to the newspaper)
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
JPMA was founded in 1968 as an organization of R&D-oriented pharmaceutical companies with the aim of contributing to the improvement of health and welfare of people around the world through research and development of ethical drugs for use in hospitals, clinics, and other medical institutions.
JPMA is dedicated to the realization of patient-participatory medicine through activities to deepen understanding of pharmaceuticals and policy recommendations for the sound development of the pharmaceutical industry.
As a member organization of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), JPMA is engaged in global activities in cooperation with other organizations to address issues related to medicine and pharmaceuticals around the world.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association